Caliway Biopharmaceuticals (6919) is a TW-listed Healthcare company in Biotechnology with a market capitalization of NT
6.0B, trading at NT
04.00 on the TWO. This SniperIQ fundamentals page covers Caliway Biopharmaceuticals's valuation, profitability (net margin -744.4%), revenue (NT
8M in FY2025), balance-sheet quality, and AI signal context — from live market data, research only.
Market CapNT
6.0B
Net Margin-744.4%
Revenue (FY25)NT
8M
Full research coverage
8-Quarter Revenue & Margin Trend
Debt Maturity & Coverage
Peer Valuation Comparison
Free Cash Flow & Owner Earnings
AI Signal + Institutional Flow
DCF Valuation Model
Frequently Asked Questions
What is Caliway Biopharmaceuticals's market cap?
Caliway Biopharmaceuticals (6919) has a market capitalization of approximately NT
6.0B, trading at NT
04.00 on the TWO. Market cap moves with the live share price.
What is Caliway Biopharmaceuticals's P/E ratio?
Caliway Biopharmaceuticals's trailing twelve-month P/E ratio is not meaningful (negative or nil earnings), with a price-to-book (P/B) of 17.2x. Valuation multiples are best compared with Healthcare sector peers rather than read in isolation.
How profitable is Caliway Biopharmaceuticals?
Caliway Biopharmaceuticals runs a net profit margin of -744.4%, a gross margin of -12.2%, and an operating margin of -1908.1%. Margins and ROE indicate how efficiently the business converts sales into profit and shareholder returns.
How much revenue does Caliway Biopharmaceuticals generate?
Caliway Biopharmaceuticals reported revenue of NT
8M for fiscal year 2025, with net income of -NT
52M and earnings per share (EPS) of -0.23. SniperIQ tracks the full 8-quarter revenue and margin trend on the research dashboard.
Does Caliway Biopharmaceuticals pay a dividend?
Caliway Biopharmaceuticals does not currently show a material trailing dividend yield; it is positioned more as a total-return name. Always confirm the latest dividend policy in the company's filings.
Is Caliway Biopharmaceuticals financially healthy?
Caliway Biopharmaceuticals carries a debt-to-equity ratio of 0.00x and a current ratio of 45.21x, with a market beta of 1.12. Lower leverage and a current ratio above 1.0 generally signal a stronger balance sheet.
Is Caliway Biopharmaceuticals a good stock to buy in 2026?
SniperIQ provides research-only market intelligence, not personalised financial advice or a buy/sell call. For Caliway Biopharmaceuticals (6919) the key facts are: market cap NT
6.0B, revenue NT
8M, 52-week range 75.1-277. Weigh valuation, profitability, growth, and balance-sheet strength against Healthcare peers and form your own view.
Track Caliway Biopharmaceuticals's full fundamentals live
Get Caliway Biopharmaceuticals's 8-quarter revenue and margin trend, peer comparison, DCF model, and AI signal on the SniperIQ research dashboard.